JNJ Icotyde: First Oral IL-23 Pill Wins CHMP

The EMA’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion on July 23, 2026 recommending marketing authorization for Icotyde (icotrokinra), Johnson & Johnson’s once-daily oral interleukin-23 (IL-23) receptor antagonist, for moderate-to-severe plaque psoriasis in adults and adolescents 12 years and older. Icotyde is the first oral medicine to target the IL-23 receptor, a pathway previously accessible only via injectable biologics.

What the EU opinion means

A CHMP positive opinion is the final scientific step before European Commission approval, which typically follows within 67 days. The Commission decision applies to all 27 EU member states. Icotyde is already FDA-approved in the US, where it launched March 18, 2026 for the same indication, making this an EU regulatory catch-up rather than a new catalyst.

JNJ closed at $263.40 on July 23. The stock is up modestly year to date, and the EU opinion is incremental to a franchise J&J has already begun building stateside.

For context on evaluating Phase 3 readouts like the ones below, our guide to reading clinical trial press releases explains what to look for.

The clinical evidence

The CHMP opinion rests on four Phase 3 studies from the ICONIC program, which enrolled roughly 2,500 patients across adults and adolescents. In the head-to-head superiority studies versus deucravacitinib (Bristol Myers Squibb’s Sotyktu, an oral TYK2 inhibitor), approximately 70% of patients reached clear or almost clear skin (IGA 0/1) at Week 16, and 55% hit PASI 90. Adverse reaction rates stayed within 1.1% of placebo through Week 16, with no new safety signals through Week 52.

The comparator matters. Deucravacitinib is the current oral standard, and beating it head-to-head on clearance is the selling point that separates Icotyde from the older oral PDE4 inhibitor apremilast (Amgen’s Otezla), which is less effective.

Why an oral IL-23 drug matters

IL-23 inhibitors are a $4B+ revenue class in psoriasis. J&J’s own Tremfya (guselkumab), an injectable IL-23p19 antibody, generates over $4 billion annually. Skyrizi (risankizumab, AbbVie) and Ilumya (tildrakizumab, Sun Pharma) round out the injectable IL-23 field. All require injections or infusions, which creates access barriers for patients who fear needles or cannot easily reach infusion centers.

Icotyde delivers the same IL-23 pathway blockade as a once-daily pill. The drug is an oral peptide that selectively binds the IL-23 receptor, blocking the signaling that drives the inflammation and skin cell overproduction characteristic of plaque psoriasis. If efficacy holds up in real-world use, it expands the treatable population beyond the roughly 15% of psoriasis patients currently on oral therapy.

What to watch next

The US launch trajectory. Icotyde has been on the US market for four months, and initial prescription data will indicate whether the head-to-head superiority claim against Sotyktu is translating into market share. J&J has also filed for first-line use, which would significantly expand the eligible population beyond patients cycling on topicals. Watch the Q3 2026 earnings call for management’s early commercial readout.

Source: J&J press release | EMA CHMP meeting highlights, July 2026